AZN
AZN clinical trials: ASTRAZENECA PLC
Every trial on ClinicalTrials.gov where ASTRAZENECA PLC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 5,466
- Trials linked
- 4,077
- As lead sponsor
- 1,389
- As collaborator
- 43
- Primary completions as lead sponsor, next 90 days
AZN on the catalyst calendar · AZN registry changes
- Primary completion Aug 31, 2027Sponsor estimatePhase 2NCT07082738A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseAstraZeneca · Chronic Obstructive Pulmonary Disease (COPD)RecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2027Sponsor estimatePhase 4NCT07944378A Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With HyperkalaemiaAstraZeneca · HyperkalemiaRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2, 2030Sponsor estimatePhase 2NCT07630714A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18...AstraZeneca · Systemic Lupus ErythematosusRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 29, 2028Sponsor estimatePhase 3NCT07024563Study of Ravulizumab in Pediatric Participants With Primary IgANAlexion Pharmaceuticals, Inc. · IgANRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 1, 2029Sponsor estimatePhase 1/Phase 2NCT06897930A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLEAstraZeneca · Lupus Erythematosus, SystemicRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 16, 2027Sponsor estimatePhase 3NCT06307652Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionAstraZeneca · Heart Failure and Impaired Kidney FunctionActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2031Sponsor estimateNo phase registeredNCT07882212GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study)AstraZeneca · Gastric CancerRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2032Sponsor estimateNo phase registeredNCT06726720UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer...AstraZeneca · Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ AllianceRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2029Sponsor estimatePhase 3NCT06989112DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of...AstraZeneca · Endometrial CancerRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 6, 2027Sponsor estimatePhase 3NCT05925803Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)AstraZeneca · Systemic SclerosisActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2026Sponsor estimatePhase 3NCT05692180A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and...AstraZeneca · AsthmaActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2032Sponsor estimateNo phase registeredNCT07654855Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired SubpopulationsAstraZeneca · Transthyretin AmyloidosisRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 27, 2029Sponsor estimatePhase 3NCT07444567Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued...AstraZeneca · AsthmaRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 26, 2029Sponsor estimatePhase 3NCT07430306A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus...AstraZeneca · Systemic Lupus ErythematosusRecruitingAZNLeadICLRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 28, 2025ActualNo phase registeredNCT07414134Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe ExacerbationAstraZeneca · Chronic Obstructive Pulmonary DiseaseCompletedAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 12, 2028Sponsor estimatePhase 1NCT07224373An Open-label Study of AZD0120 in Adults With Multiple SclerosisAstraZeneca · Multiple SclerosisRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 11, 2028Sponsor estimatePhase 1/Phase 2NCT07109219Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic LeukemiaAstraZeneca · B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingAZNLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2028Sponsor estimateNo phase registeredNCT07088991Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsiaAstraZeneca · NeurofibromatosisRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 22, 2027Sponsor estimatePhase 2/Phase 3NCT06834932A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With DyslipidaemiaAstraZeneca · DyslipidaemiaActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2027Sponsor estimatePhase 1NCT06218914Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsAstraZeneca · Non-small Cell Lung CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 27, 2026ActualNo phase registeredNCT05677139A Study for Observing Severe Asthma in Patients Treated With TezepelumabAstraZeneca · AsthmaCompletedAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 20, 2026ActualPhase 4NCT03953300Benralizumab Airway Remodeling Study in Severe Eosinophilic AsthmaticsAstraZeneca · AsthmaCompletedAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 16, 2028Sponsor estimatePhase 2NCT07941609A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLCAstraZeneca · Non-small Cell Lung Cancer (NSCLC)Not yet recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2028Sponsor estimatePhase 3NCT07520162A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With TezepelumabAstraZeneca · Chronic Rhinosinusitis With Nasal PolypsRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 20, 2026ActualNo phase registeredNCT06566885Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in RussiaAstraZeneca · Severe AsthmaCompletedAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 5,441 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner